Wake Bio develops technologies for the reversible preservation of whole organisms using machine learning and rapid experimentation. Their primary focus is advancing reversible human cryopreservation techniques. This work aims to provide patients with the option to survive until a cure for their condition is available.
Funding
Funding not disclosed
Founders
Product
Problem
The current medical paradigm offers limited options for patients with terminal illnesses, often leaving them with no recourse but to accept their prognosis. This necessitates the development of advanced preservation techniques that can provide individuals with the opportunity to survive until effective treatments become available.
Solution
Wake Bio is developing technologies for the reversible preservation of whole organisms, aiming to provide a pathway for individuals to survive until a cure for their condition is discovered. The company utilizes machine learning and rapid experimentation to accelerate the development of these advanced preservation methods. This approach focuses on creating a state where biological systems can be safely preserved and later revived, offering a novel therapeutic option for patients facing currently untreatable diseases.
Target Audience
The primary target audience includes individuals with terminal illnesses seeking extended survival options and the broader medical and scientific community focused on regenerative medicine and cryobiology.
Features
- Development of reversible preservation technologies for whole organisms.
- Application of machine learning algorithms to optimize preservation protocols.
- Utilization of rapid experimentation cycles to accelerate research and development.
- Focus on achieving long-term, stable preservation with subsequent successful revival.